MTOR and breast cancer: To further confirm whether DUXAP8 mediates the radioresistance of BC cells by activating the PI3K/AKT/mTOR pathway, MCF-7/T47D cells overexpressing DUXAP8 were treated with a selective inhibitor of PI3K (NVP-BKM120), and the cell viability upon irradiation was examined determined by CCK-8 assay.